Novartis Dismisses Some Exelon Patent Claims
A federal judge on Thursday approved Novartis Pharmaceuticals Corp.'s requests to dismiss claims for infringement of one patent involved in a multidistrict dispute over Exelon, the Swiss drug maker's Alzheimer's treatment....To view the full article, register now.
Already a subscriber? Click here to view full article